Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease

Pediatrics International

Volumn 47, Issue 4, 2005, Pages 397-403

  Saji, Tsutomu ^a,d   Nakazawa, Makoto ^b   Harada, Kensuke ^c  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE   (Japan)

Author keywords

Congenital heart disease; Monoclonal antibody; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTIFICIAL VENTILATION; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; DYSPNEA; FEMALE; FEVER; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SUPRAVENTRICULAR TACHYCARDIA; VOMITING;

ANTIBODIES, MONOCLONAL; COMORBIDITY; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 23844518513     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200x.2005.02089.x     Document Type: Review

References (27)

1. Hall CB, McBride JT. Respiratory Syncytial Virus from chimps with colds to conundrums and cures. N. Engl. J. Med. 1991; 325: 57-8.
2. Hall CB, Walsh EE, Long CE et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect Dis 1991; 164: 693-8.
3. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 week's gestation. Pediatrics 1991; 88: 527-32.
4. Groothuis JR, Gutierretz KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82: 199-203.
5. MacDonald NE, Hall CB, Suffin SC et al. Respiratory syncytial viral infection in infants with congenital heart disease. N. Eng. J. Med. 1982; 307: 397-400.
6. Mito K, Chiba Y, Nakao T. Respiratory syncytial virus infection in children with congenital heart disease. Kosankinbyo Kenkyusho Zasshi 1985; 37: 169-76 (in Japanese).
7. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr. Cardiol. 1996; 17: 163-8.
8. Fujimura M. A Study on Clarification of Problems and Solutions Concerning Appropriate Use of Pediatric Drugs. (Supervisor: K. Onishi.) Study report for Takamatsu Junior College, Kagawa, Japan, 2001 (in Japanese).
9. The IMpact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
10. Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr. Int. 2002; 44: 235-41.
11. Glezen WP, Taber LH, Frank AL et al. Risk of primary infection and reinfection with respiratory syncytial virus. AJDC 1986; 140: 543-6.
12. Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N. Eng J. Med. 1986; 315: 77-81.
13. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997; 176: 1215-24.
14. Mili F, Edmonds LD, Khoury MJ et al. Prevalence of birth defects among low birth weight infants. A population study. AJDC 1991; 145: 1313-18.
15. Khoury MJ, Erickson JD, Crdero JF et al. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82: 83-90.
16. Carlgren LE, Ericson A, Kallen B. Monitoring of congenital cardiac defects. Pediatr. Cardiol. 1987; 8: 247-56.
17. Powell TG, Pharoah POD, Cooke RWI. Congenital defects and the care of low birthweight infants. Early Hum. Dev. 1988; 16: 173-83.
18. Takeuchi Y. Epidemiological and clinical features of influenza and respiratory syncytial virus infections among children in Japan. Acta Paediatr. Jpn. 1988; 30: 231-9.
19. Kaneko M, Watanabe J, Kuwahara M et al. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan. J. Infect. 2000; 44: 240-3.
20. Saez-Llorens X, Null E, Steichen J et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 1998; 17: 787-91.
21. Feltes T, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003; 143: 532-40.
22. Simoes EAF, Sondheimer HM, Top FH Jr et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J. Pediatr. 1998; 133: 492-9.
23. Doi H, Baba S, Iida M et al. An Infant with Down's Syndrome in Whom Severe Neurological Sequelae Occurred After Resuscitation for Cardiopulmonary Arrest Associated with Exacerbation of Bronchiolitis After Surgery for VSD and ASD - a Strong Request for Prompt Expansion of the Indications for Palivizumab. The 38th General/Academic Meeting of the Japanese Society of Pediatric Cardiology and Cardiac Surgery. 2002 (in Japanese).
24. Watanabe K, Harai T, Watanabe A et al. Severe RS Virus Infection in Two Patients with Congenital Heart Disease - Evidence of Necessity for Inclusion of Congenital Heart Disease as an Indication for Palivizumab. The 38th General/Academic Meeting of the Japanese Society of Pediatric Cardiology and Cardiac Surgery 2003 (in Japanese).
25. Tulloh R, Marsh M, Blackburn M et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol. Young 2003; 13: 420-3.
26. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr. Infect. Dis. J. 2004; 23: S41-5.
27. American Academy of Pediatrics. Policy Statement: Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 112: 1442-6.